In the growing field of therapeutic antibodies, drug developers are continually searching for new strategies to improve efficacy. Optimization of antibody molecules by Fc engineering is a major opportunity in this area. Potency can be increased by enhancing antibody-dependent cellular cytotoxicity (ADCC). 100% fucose-free antibodies in glycan moieties show much higher ADCC activity than normally fucosylated antibodies.
Through our partnership with BioWa, we can help you take advantage of this strategy. By fully removing fucose content, BioWa’s POTELLIGENT® Technology can increase the potency and efficacy of your antibody drugs. The POTELLIGENT® CHOK1SV® cell line technology enables the rapid expression of highly productive and stable recombinant cell lines
Through our partnership with BioWa, we can help you take advantage of our established CHOK1SV® cell line lineage. By fully removing fucose content, BioWa’s POTELLIGENT® Technology can increase the potency and efficacy of your antibody drugs.
The POTELLIGENT® CHOK1SV® cell line is available under a license.
Contact us to find out more.